HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $214

Belite Bio, Inc. ADR

Belite Bio, Inc. ADR

BLTE

0.00

HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ: BLTE) with a Buy and raises the price target from $200 to $214.